CHRS
HealthcareCoherus Oncology, Inc. · Biotechnology · $200M
CHRS — Key Takeaways
✅ Strengths
⚠️ Areas of Concern
CHRS — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| Apr 8, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | 0.0 |
| Apr 7, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | 0.0 |
| Apr 6, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | 0.0 |
| Apr 5, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | 0.0 |
| Apr 4, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | 0.0 |
| Apr 3, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | 0.0 |
| Apr 2, 2026 | 44.7 | 37.9 | 19.0 | 37.5 | 53.1 | 100.0 | — |
CHRS — Pillar Breakdown
Quality
— 37.9/100 (25%)Coherus Oncology, Inc. has average quality metrics, with room for improvement in margins or capital efficiency.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Asset productivity — how much gross profit each dollar of assets generates.
Free cash flow relative to market value.
Growth
— 37.5/100 (20%)Coherus Oncology, Inc. shows steady but unspectacular growth, typical for mature companies.
Revenue trajectory over the last twelve months.
Compound annual revenue growth rate over 3 years.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 53.1/100 (15%)Coherus Oncology, Inc. has some risk factors including moderate leverage or solvency concerns.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 100.0/100 (15%)Coherus Oncology, Inc. appears attractively valued relative to its earnings, cash flows, and sector peers.
Inverse of forward P/E — higher yield means cheaper stock.
Moat
— 19/100 (30%)Coherus Oncology, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for CHRS.
Score Composition
More Stock Analysis
How is the CHRS UQS Score Calculated?
The UQS (Unified Quality Score) for Coherus Oncology, Inc. is calculated using a proprietary 5-pillar framework with 25 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Coherus Oncology, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Coherus Oncology, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.